Genprex, Inc.
GNPX
Last
$2.71
Day
-1.5%
1y
-98.9%
5y
-100.0%
52w
-99.8%
SPY YTD
+13.3%
XLV
+8.1%
Earnings
2026-11-1333d
EMA 21
3.09
EMA 50
4.67
EMA 200
84.70
20d high
-34.5%
5y high
-100.0%
5y range
0th
Positions held
Your positionsGNPX isn't in your positions.
Add it to see shares, cost, and P&L here.
Score
-9
Hold
avoid
Signal
Sell
Target
$3.31
Stop
$2.29
Stop distance
15.5%
Target vs last
+22.1%
Fundamentals
| Market cap | $2.25M | Enterprise value | -$12.90M | Trailing P/E | — | Forward P/E | -1.26 |
| PEG | — | Price / book | 0.09 | Beta | -0.98 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -2.0% | ROA | -94.5% | Debt / equity | — |
| Current ratio | 6.77 | Free cash flow | -$10.58M | Analyst recommendation | none | Mean target | — |
| 52w high | $1,210.00 | 52w low | $2.53 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$4.4M | -$4.5M | -$3.8M | -$3.8M | -$4.7M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$4.5M | -$4.5M | -$3.5M | -$3.3M | -$4.7M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — |
| Net income | -$16.2M | -$21.1M | -$30.9M | -$23.7M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$15.5M | -$21.2M | -$31.1M | -$23.8M | — |
Headline scan
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-08 · Genprex to Present at the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-01 · Andelyn Biosciences to Scale Manufacturing for Genprex's Diabetes Gene Therapy Program
2026-08-03 · Genprex Shares Rise After Collaboration With Roche Diagnostics
2026-08-03 · Genprex Announces Collaboration with Roche Diagnostics for Biomarker Assay Validation Studies
Price (daily)
Full chart · RSI · MACD · patternsGNPX · daily-22.3% over 13 sessions
Close EMA21 EMA50 EMA200
Quarterly · revenue, net income, margins
Revenue Net income Gross margin Op margin